SUBSCRIBE
SUBSCRIBE
News   FDA

Pfizer Inc.'s (JOBS) Bone-Drug Fablyn Fails to Win U.S. Approval

January 17, 2009 | 
1 min read
Jan. 16 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, failed to win U.S. approval to sell a treatment for women with weak bones that may be linked to an increase in deaths.
FDA Approvals Regulatory
Pfizer
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Close-up of medical ampoule production line/iStock
Manufacturing
Novo-Acquired Catalent Plant Plagued by Unresolved Pest, Contamination Issues, FDA Finds
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
 · 
1 min read
 · 
Lori Ellis
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Regulatory
Stealth’s Flight Path Returns to FDA for Rejected Barth Drug
August 21, 2025
 · 
1 min read
 · 
Annalee Armstrong